Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Saul E. Rivkin"'
Autor:
Mehmet F. Fer, Chirag A. Shah, Erin D. Ellis, Heather L. Sloan, Erik Bailey, Gary E. Goodman, Tanya A. Wahl, Peter Jiang, Saul E. Rivkin, Charles W. Drescher, Dan Velijovich, Amy E. Bondurant, Henry G. Kaplan, Desiree Iriarte, James Moon
Publikováno v:
International Journal of Gynecologic Cancer. 29:325-333
ObjectiveOur goals were to: establish the maximum-tolerated dose of olaparib tablets combined with metronomic carboplatin and paclitaxel in patients with relapsed high-grade serous ovarian cancer; evaluate dose-limiting toxicities; and evaluate effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbacf5f9337c3066e219a50392843952
https://doi.org/10.1136/ijgc-2018-000035
https://doi.org/10.1136/ijgc-2018-000035
Autor:
Paul Frankel, Min S. Park, Paul Lin, Amy Hakim, Mark T. Wakabayashi, Mihaela C. Cristea, Benjamin Paz, Lucille Leong, Thanh H. Dellinger, Dean Lim, Timothy W. Synold, Saul E. Rivkin, Ernest S. Han, Joseph Chao, Robert J. Morgan, Vincent Chung, Mary Carroll, Neal Prakash
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: To evaluate intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies that are primarily confined to the peritoneal cavity in a phase I trial. METHODS: Using a 3+3 dose escalation of IP nab-paclitaxel on days 1, 8, and 15 of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3456f8f47cf80c6b1fa3830eff21f43
https://pubmed.ncbi.nlm.nih.gov/30623229
https://pubmed.ncbi.nlm.nih.gov/30623229
Autor:
Bryan Goldman, Ralph Wong, Eileen M. O'Reilly, James L. Abbruzzese, Kendrith M. Rowland, Philip A. Philip, Cecilia M. Fenoglio-Preiser, Charles D. Blanke, Christopher L. Corless, Jacqueline Benedetti, Saul E. Rivkin, James N. Atkins, B. Mirtsching, Patrick J. Flynn, Alok A. Khorana
Publikováno v:
Journal of Clinical Oncology. 28:3605-3610
Purpose Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be356552acc7358a41e5e13694e1562e
https://doi.org/10.1200/jco.2009.25.7550
https://doi.org/10.1200/jco.2009.25.7550
Autor:
Jane Arthur, Judith A. Malmgren, Saul E. Rivkin, Carolyn Y. Muller, James Moon, Heather Gerould, Desiree Iriarte
Publikováno v:
Clinical Ovarian Cancer. 2:112-117
Purpose Our objective was to find the maximum tolerated combination dose of daily oral lapatinib and weekly carboplatin (C) and paclitaxel (T; metronomic mCT). The secondary objectives included toxicity, safety, and efficacy of response to therapy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cec00e2522841ec1dbd53e6f998cb237
https://doi.org/10.3816/coc.2009.n.018
https://doi.org/10.3816/coc.2009.n.018
Autor:
Jackie Szymonifka, John Crowley, Antje Hoering, Bart Barlogie, Morie A. Gertz, Saul E. Rivkin, Madhav V. Dhodapkar
Publikováno v:
Blood. 113:793-796
The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously. The development of prognostic models in WM has been fraught by limited follow-up in current studies. Here, we update the outcome of a prospective WM trial with a medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c476ac936ca63f79bc1899cceeb39f
https://doi.org/10.1182/blood-2008-07-172080
https://doi.org/10.1182/blood-2008-07-172080
Autor:
Elisabeth J. Rushing, Cathryn Rankin, Robert B. Livingston, Deborah T. Blumenthal, Saul E. Rivkin, Alexander M. Spence, Mitchel S. Berger, Harmon J. Eyre, Allen Cohn, Keith J. Stelzer, Stephen H. Petersdorf
Publikováno v:
Cancer. 113:559-565
BACKGROUND. The poor prognosis reported for patients with high‒grade glial neoplasms indicates a need for the development of multimodality therapeutic approaches. The addition of chemotherapy has contributed variably to increased survival. The obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21ad9abc694c3ebb3753b39a55fbd34
https://doi.org/10.1002/cncr.23585
https://doi.org/10.1002/cncr.23585
Autor:
Celestia S. Higano, Kenneth J. Russell, Saul E. Rivkin, James R. Faulkner, Maha Hussain, Frederick J. Meyers, Wael Sakr, Laurence H. Baker, E. David Crawford, Catherine M. Tangen
Publikováno v:
Cancer
BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients. METHO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a15de61fdc951ddc65fdddaef5728325
https://doi.org/10.1002/cncr.23420
https://doi.org/10.1002/cncr.23420
Autor:
Edward L. Trimble, Frederick R. Ueland, Saul E. Rivkin, Andre T. Baron, D. Connolly, Jonathan S. Berek, Elise C. Kohn, Maurie Markman, Mary L. Disis
Publikováno v:
International Journal of Gynecological Cancer. 16:463-469
Ovarian cancer remains the most lethal gynecological malignancy. The 5th Biennial Symposium overviewed the progress of ovarian cancer research over the last few years. Molecularly based technologies have allowed the identification of multiple biomark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::558262a9eb05fc69f8177c729f393d2a
https://doi.org/10.1111/j.1525-1438.2006.00559.x
https://doi.org/10.1111/j.1525-1438.2006.00559.x
Autor:
Michael Tanaka, James L. Abbruzzese, Heinz-Josef Lenz, Marcus A. Neubauer, Sheryl McCoy, John S. Macdonald, Shaker R. Dakhil, Saul E. Rivkin, Robert P. Whitehead
Publikováno v:
Investigational New Drugs. 24:335-341
Purpose: The purpose of this Phase II multi-institutional trial was to determine the efficacy and toxicity of R115777 in previously untreated patients with metastatic colorectal carcinoma. Patients and methods: Patients were required to have histolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c9ce416f2fc8e0889c2692979341ba
https://doi.org/10.1007/s10637-005-4345-3
https://doi.org/10.1007/s10637-005-4345-3
Autor:
Silvana Martino, Craig Allred, Saul E. Rivkin, Martin D. Abeloff, Laura F. Hutchins, C. Kent Osborne, Peter M. Ravdin, Danika Lew, Stephanie Green, Alan P. Lyss
Publikováno v:
Journal of Clinical Oncology. 23:8313-8321
Purpose We evaluated the efficacy of cyclophosphamide, methotrexate, and fluorouracil (CMF) versus cyclophosphamide, doxorubicin, and fluorouracil (CAF) in node-negative breast cancer patients with and without tamoxifen (TAM), overall and by hormone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ac1cb8c6ddb818caa904aa8996ccbe
https://doi.org/10.1200/jco.2005.08.071
https://doi.org/10.1200/jco.2005.08.071